Health
SEROLOGICAL RESPONSES AFTER SARS‐COV‐2 VACCINATION FIRST DOSE IN PATIENTS WITH LYMPHOID MALIGNANCY: FIRST INTERIM ANALYSIS OF THE UK PROSECO STUDY – Wiley
Click on the article title to read more.
Introduction: COVID-19 is thought to be more frequent and severe in patients with cancer. Lymphoma patients may be especially vulnerable, due to the immunodeficiency and immune dysregulation caused by the lymphoma itself and the antitumor treatments. This…
Continue Reading
-
Business6 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Business10 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Noosa News5 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
General24 hours agoFederal Labor makes $100m Canberra convention centre funding pledge for planning, new aquatic centre